Browse > Article
http://dx.doi.org/10.15324/kjcls.2019.51.1.26

Investigation of the Molecular Diagnostic Market in Animals  

Park, Chang-Eun (Department of Biomedical Laboratory Science, Molecular Diagnostics Research Institute, Namseoul University)
Park, Sung-Ha (IVD R&D Group, IVD Business Team, Health and Medical Equipment Division, Samsung Electronics Co., Ltd.)
Publication Information
Korean Journal of Clinical Laboratory Science / v.51, no.1, 2019 , pp. 26-33 More about this Journal
Abstract
Recently, the rapid growth of the companion animal market has led to the development of animal disease diagnosis kits. Therefore, the utility of the introduction of biomarkers for the development of animal molecular diagnostics is being reevaluated. A good biomarker should be precise and reliable, distinguish between normal and diseased states, and differentiate between different diseases. Recently reported genetic markers, tumor markers (cell free DNA, circulating tumor cells, granzyme, and skin tumors), and others (brucellosis, programmed death recovery-1, symmetric dimethylarginine, periostin, and cysteinyl leukotrien) have been developed. The biomarkers are used for risk prediction or for the screening, diagnosis, and monitoring of disease progression. The most important criteria for related biomarkers are disease specificity. Many potential biomarkers have emerged from laboratory and test studies, but they have not been validated in independent or large-scale clinical studies. Candidate biomarkers evaluate disease associations, verify the effectiveness of biomarkers for early detection and disease progression, and incorporate them into humans and animals. In the future, it will be necessary to reevaluate the utility of well-structured biomarker-based research and study the development of kits that can be used in on-site tests in accordance with the trends introduced in the diagnosis of animal diseases.
Keywords
Biomarkers; Companion animal; Disease progression; In vitro diagnosis; Tumor marker;
Citations & Related Records
Times Cited By KSCI : 3  (Citation Analysis)
연도 인용수 순위
1 Boudreau CE. An update on cerebrovascular disease in dogs and cats. Vet Clin North Am Small Anim Pract. 2018;48:45-62. https://doi.org/10.1016/j.cvsm.2017.08.009.   DOI
2 Hokamp JA, Nabity MB. Renal biomarkers in domestic species. Vet Clin Pathol. 2016;45:28-56. https://doi.org/10.1111/vcp.12333.   DOI
3 Xenoulis PG. Diagnosis of pancreatitis in dogs and cats. J Small Anim Pract. 2015;56:13-26. https://doi.org/10.1111/jsap.12274.   DOI
4 Shah R, Jones E, Vidart V, Kuppen PJ, Conti JA, Francis NK. Biomarkers for early detection of colorectal cancer and polyps: systematic review. Cancer Epidemiol Biomarkers Prev. 2014;23:1712-1728. https://doi.org/10.1158/1055-9965.EPI-14-0412.   DOI
5 Yoon HJ, An HJ, Kim CH, Kim YH, Wee SH, Moon JS. Performance assessment of registration, sales and the regulatory management system of in vitro diagnostic veterinary medical reagents in Korea. J Prev Vet Med. 2015;39:119-125. http://doi.org/10.13041/jpvm.2015.39.3.119.   DOI
6 Pang LY, Argyle DJ. Veterinary oncology: Biology, big data and precision medicine. Vet J. 2016;213:38-45. https://doi.org/10.1016/j.tvjl.2016.03.009.   DOI
7 An HJ, Yoon HJ, Kim CH, Wee SH, Moon JS. Performance assessment and improvement plan of the regulatory management system of veterinary medical devices in Korea. Korean J Vet Res. 2015;55:97-103.   DOI
8 Gibson TJ, Jackson EL. The economics of animal welfare. Rev Sci Tech. 2017;36:125-135. https://doi.org/10.20506/rst.36.1.2616.   DOI
9 Pomba C, Rantala M, Greko C, Baptiste KE, Catry B, van Duijkeren E, et al, Public health risk of antimicrobial resistance transfer from companion animals. J Antimicrob Chemother. 2017;72:957-968. https://doi.org/10.1093/jac/dkw481.
10 Talbot TR, Bratzler DW, Carrico RM, Diekema DJ, Hayden MK, Huang SS, et al. Public reporting of health care-associated surveillance data: recommendations from the healthcare infection control practices advisory committee. Ann Intern Med. 2013;159:631-635. https://doi.org/10.7326/0003-4819-159-9-201311050-0001.   DOI
11 Morris JS. Genomic and proteomic profiling for cancer diagnosis in dogs. Vet J. 2016;215:101-109. https://doi.org/10.1016/j.tvjl.2016.01.003.   DOI
12 De Loor J, Daminet S, Smets P, Maddens B, Meyer E. Urinary biomarkers for acute kidney injury in dogs. J Vet Intern Med. 2013;27:998-1010. https://doi.org/10.1111/jvim.12155.   DOI
13 Finocchiaro LME, Glikin GC. Recent clinical trials of cancer immunogene therapy in companion animals. World J Exp Med. 2017;7:42-48. https://doi.org/10.5493/wjem.v7.i2.42.   DOI
14 Langhorn R, Willesen JL. Cardiac troponins in dogs and cats. J Vet Intern Med. 2016;30:36-50. https://doi.org/10.1111/jvim.13801.   DOI
15 Carreton E, Morchon R, Montoya-Alonso JA. Cardiopulmonary and inflammatory biomarkers in heartworm disease. Parasit Vectors. 2017;10:534. https://doi.org/10.1186/s13071-017-2448-2.   DOI
16 Jeffery U, Staber J, LeVine D. Using the laboratory to predict thrombosis in dogs: An achievable goal?. Vet J. 2016;215:10-20. https://doi.org/10.1016/j.tvjl.2016.03.027.   DOI
17 Jeon BH. Diagnosis of disease using blood biomarker discovery trend, BRIC View 2017-T24. [Internet]. Pohang: Biological research information center; 2017 [cited 2019 January 16]. Available from: http://www.ibric.org/myboard/read.php?Board=report&id=2767.
18 Kycko A, Reichert M. Proteomics in the search for biomarkers of animal cancer. Curr Protein Pept Sci. 2014;15:36-44.   DOI
19 Rodriguez-Antona C, Taron M. Pharmacogenomic biomarkers for personalized cancer treatment. J Intern Med. 2015;277:201-217. https://doi.org/10.1111/joim.12321.   DOI
20 Bussard KM, Siracusa LD. Understanding mitochondrial polymorphisms in cancer. Cancer Res. 2017;77:6051-6059. https://doi.org/10.1158/0008-5472.CAN-17-1939.   DOI
21 Hayes J, Peruzzi PP, Lawler S. MicroRNAs in cancer: biomarkers, functions and therapy. Trends Mol Med. 2014;20:460-469. https://doi.org/10.1016/j.molmed.2014.06.005.   DOI
22 Gielis EM, Ledeganck KJ, De Winter BY, Del Favero J, Bosmans JL, Claas FH, et al. Cell-free DNA: An upcoming biomarker in transplantation. Am J Transplant. 2015;15:2541-2451. https://doi.org/10.1111/ajt.13387.   DOI
23 Previdi MC, Carotenuto P, Zito D, Pandolfo R, Braconi C. Noncoding RNAs as novel biomarkers in pancreatic cancer: what do we know? Future Oncol. 2017;13:443-453. https://doi.org/10.2217/fon-2016-0253.   DOI
24 Barani B, Rajasingh S, Rajasingh J. Exosomes: outlook for future cell-free cardiovascular disease therapy. Adv Exp Med Biol. 2017;998:285-307. https://doi.org/10.1007/978-981-10-4397-0_19.   DOI
25 Burnett DL, Cave NJ, Gedye KR, Bridges JP. Investigation of cell-free DNA in canine plasma and its relation to disease. Vet Q. 2016;36:122-129. https://doi.org/10.1080/01652176.2016.1182230.   DOI
26 Cheng F, Su L, Qian C. Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer. Oncotarget. 2016;7:48832-48841. https://doi.org/10.18632/oncotarget.9453.   DOI
27 Ulrich BC, Paweletz CP. Cell-free DNA in oncology: Gearing up for clinic. Ann Lab Med. 2018;38:1-8. https://doi.org/10.3343/alm.2018.38.1.1.   DOI
28 Butler TM, Spellman PT, Gray J. Circulating-tumor DNA as an early detection and diagnostic tool. Curr Opin Genet Dev. 2017;42:14-21. https://doi.org/10.1016/j.gde.2016.12.003.   DOI
29 Aarthy R, Mani S, Velusami S, Sundarsingh S, Rajkumar T. Role of circulating cell-free DNA in cancers. Mol Diagn Ther. 2015;19:339-350. https://doi.org/10.1007/s40291-015-0167-y.   DOI
30 Peng M, Chen C, Hulbert A, Brock MV, Yu F. Non-blood circulating tumor DNA detection in cancer. Oncotarget. 2017;8:69162-69173. https://doi.org/10.18632/oncotarget.19942.   DOI
31 Hohenhaus AE, Kelsey JL, Haddad J, Barber L, Palmisano M, Farrelly J, et al. Canine cutaneous and subcutaneous soft tissue sarcoma: An evidence-based review of case management. J Am Anim Hosp Assoc. 2016;52:77-89. https://doi.org/10.5326/JAAHA-MS-6305.   DOI
32 Inoue A, Maeda S, Kinoshita R, Tsuboi M, Yonezawa T, Matsuki N. Density of tumor-infiltrating granzyme B-positive cells predicts favorable prognosis in dogs with transitional cell carcinoma. Vet Immunol Immunopathol. 2017;190:53-56. https://doi.org/10.1016/j.vetimm.2017.07.001.   DOI
33 Kanojia D1, Garg M, Gupta S, Gupta A, Suri A. Sperm-associated antigen 9 is a novel biomarker for colorectal cancer and is involved in tumor growth and tumorigenicity. Am J Pathol. 2011;178:1009-1020. https://doi.org/10.1016/j.ajpath.2010.11.047.   DOI
34 Sledge DG, Webster J, Kiupel M. Canine cutaneous mast cell tumors: A combined clinical and pathologic approach to diagnosis, prognosis, and treatment selection. Vet J. 2016;215:43-54. https://doi.org/10.1016/j.tvjl.2016.06.003.   DOI
35 McDermott DF, Atkins MB. PD-1 as a potential target in cancer therapy. Cancer Med. 2013;2:662-673. https://doi.org/10.1002/cam4.106.   DOI
36 Muenst S, Soysal SD, Tzankov A, Hoeller S. The PD-1/PD-L1 pathway: biological background and clinical relevance of an emerging treatment target in immunotherapy. Expert Opin Ther Targets. 2015;19:201-211.   DOI
37 Salmaninejad A, Khoramshahi V, Azani A, Soltaninejad E, Aslani S, Zamani MR, et al. PD-1 and cancer: molecular mechanisms and polymorphisms. Immunogenetics. 2018;70:73-86. https://doi.org/10.1007/s00251-017-1015-5.   DOI
38 Hartley G, Faulhaber E, Caldwell A, Coy J, Kurihara J, Guth A, et al. Immune regulation of canine tumour and macrophage PDL1 expression. Vet Comp Oncol. 2016;10:1-16.
39 Chiku VM, Silva KL, de Almeida BF, Venturin GL, Leal AA, de Martini CC, et al. PD-1 function in apoptosis of T lymphocytes in canine visceral leishmaniasis. Immunobiology. 2016;221:879-888.   DOI
40 Shah R, Jones E, Vidart V, Kuppen PJ, Conti JA, Francis NK. Biomarkers for early detection of colorectal cancer and polyps: systematic review. Cancer Epidemiol Biomarkers Prev. 2014;23:1712-1728. https://doi.org/10.1158/1055-9965.EPI-14-0412.   DOI
41 Nijveldt RJ, Van Leeuwen PA, Van Guldener C, Stehouwer CD, Rauwerda JA, Teerlink T. Net renal extraction of asymmetrical (ADMA) and symmetrical (SDMA) dimethylarginine in fasting humans. Nephrol Dial Transplant. 2002;17:1999-2002.   DOI
42 Paltrinieri S, Gradoni L, Roura X, Zatelli A, Zini E. Laboratory tests for diagnosing and monitoring canine leishmaniasis. Vet Clin Pathol. 2016;45:552-578. https://doi.org/10.1111/vcp.12413.   DOI
43 Nijveldt RJ, Teerlink T, van Guldener C, Prins HA, van Lambalgen AA, Stehouwer CD, et al. Handling of asymmetrical dimethylarginine and symmetrical dimethylarginine by the rat kidney under basal conditions and during endotoxaemia. Nephrol Dial Transplant. 2003;18:2542-2550.   DOI
44 Al Banchaabouchi M, Marescau B, Possemiers I, D'Hooge R, Levillain O, De Deyn PP. NG, NG-dimethylarginine and NG, NG-dimethylarginine in renal insufficiency. Pflugers Arch. 2000;439:524-531.
45 Schepers E, Speer T, Bode-Boger SM, Fliser D, Kielstein JT. Dimethylarginines ADMA and SDMA: the real water-soluble small toxins? Semin Nephrol. 2014;34:97-105.   DOI
46 Fleck C, Schweitzer F, Karge E, Busch M, Stein G. Serum concentrations of asymmetric (ADMA) and symmetric (SDMA) dimethylarginine in patients with chronic kidney diseases. Clin Chim Acta. 2003;336:1-12.   DOI
47 Kielstein JT, Salpeter SR, Bode-Boeger SM, Cooke JP, Fliser D. Symmetric dimethylarginine (SDMA) as endogenous marker of renal function-a meta-analysis. Nephrol Dial Transplant. 2006;21:2446-2451.   DOI
48 Feliers D, Lee DY, Gorin Y, Kasinath BS. Symmetric dimethylarginine alters endothelial nitric oxide activity in glomerular endothelial cells. Cell Signal. 2015;27:1-5.   DOI
49 Lee SJ, Park S. Usefulness of the neutrophil gelatinase-associated lipocalin (NGAL) kit for acute kidney injury patients at the emergency medical center in Daegu. Korean J Clin Lab Sci. 2016;48:49-53. https://doi.org/10.15324/kjcls.2016.48.2.49.   DOI
50 Woodruff PG, Boushey HA, Dolganov GM, Barker CS, Yang YH, Donnelly S, et al. Genome-wide profiling identifies epithelial cell genes associated with asthma and with treatment response to corticosteroids. Proc Natl Acad Sci USA. 2007;104:15858-63.   DOI
51 Cai C, Yang J, Hu S, Zhou M, Guo W. Relationship between urinary cys\-teinyl leukotriene E4 levels and clinical response to antileukotriene treat\-ment in patients with asthma. Lung. 2007;185:105-12.   DOI
52 Specjalski K, Chelminka M, Jassem E. YKL-40 protein correlates with the phenotype of asthma. Lung. 2015;193:189-94.   DOI
53 Sim DW, Lee JH. Biomarkers of adult asthma and personalized medicine. Allergy Asthma Respir Dis. 2016;4:4-13. http://doi.org/10.4168/aard.2016.4.1.4.   DOI
54 Schlotterer, C. The evolution of molecular markers-just a matter of fashion? Nat Rev Genet. 2004;5:63-69.   DOI
55 Aronson JK, Ferner RE. Biomarkers-A general review. Curr Protoc Pharmacol. 2017;76:1-17. https://doi.org/10.1002/cpph.19.
56 Tyers, M, Mann, M. From genomics to proteomics. Nature. 2003;422:193-197.   DOI
57 Mayeux, R. Biomarkers: potential uses and limitations. NeuroRx. 2004;1:182-188.   DOI
58 Lesko, LJ, Atkinson, A. Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: criteria, validation, strategies. Annu Rev Pharmacol Toxicol. 2001;41:347-366.   DOI
59 Bhattacharya SK, Lee RK, Grus FH. Molecular biomarkers in glaucoma. Invest Ophthalmol Vis Sci. 2013;54:121-131.   DOI
60 Purewal R, Christley R, Kordas K, Joinson C, Meints K, Gee N, et al. Companion animals and child/adolescent development: A systematic review of the evidence. Int J Environ Res Public Health. 2017;14. pii: E234. http://doi.org/10.3390/ijerph14030234.
61 Allan R. Companion animal medicine: fresh challenges in the evidence-based, client-focused fast lane. Vet Rec. 2016; 179:38-40. http://doi.org/10.1136/vr.i3156.   DOI
62 An HJ, Hyang-Jin Yoon, Chung-Hyun Kim, Sung-Hwan Wee, Jin-San Moon. Performance assessment and improvement plan of the regulatory management system of veterinary medical devices in Korea. Korean J Vet Res. 2015;55:97-103.   DOI
63 Friedman E, Krause-Parello CA. Companion animals and human health: benefits, challenges, and the road ahead for human-animal interaction. Rev Sci Tech. 2018;37:71-82. http://doi.org/10.20506/rst.37.1.2741.   DOI
64 Rachakonda V, Pan TH, Le WD. Biomarkers of neurodegenerative disorders: how good are they? Cell Res. 2004;14:349-358.   DOI